Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure

Heart failure is an important medical, social and economic problem around the world. In recent years, a number of diagnostic and prognostic biological markers of blood in cardiovascular diseases have been studied. Identification of new biological markers, analysis of their pathophysiological aspects and changes in concentration under the influence of various treatment options, allow us to understand many pathogenetic features of the development and course of heart failure. In recent decades, natriuretic peptides have been introduced into clinical practice, which are widely used as reliable markers for diagnostic and prognostic assessment. Growth differentiation factor-15 is a cytokine belonging to the family of transforming growth factors, the activity of which is significantly increased under stress and inflammation. In patients with chronic heart failure, the concentration of this marker is associated with an increased risk of overall mortality and adverse cardiovascular events; in patients with heart failure with preserved left ventricular ejection fraction, the use of the marker showed prognostic and diagnostic significance. Data from the Framingham Heart Study showed that growth differentiation factor-15 was the only marker in multivariate analysis that showed a statistically significant association with all adverse cardiovascular events. Eight studies showed that overexpression of growth differentiation factor-15 was associated with an increased risk of mortality in patients with heart failure. It was shown that growth differentiation factor-15 as a prognostic marker in patients with acute heart failure is not inferior to the brain natriuretic peptide precursor. To confirm the value of this marker in blood in patients with heart failure, it is necessary to conduct extensive prospective randomized clinical trials.

1. Braunwald E. Heart failure. JACC Heart Fail. US National Institutes of Health. 2013; 1(1): 1-20. DOI: 10.1016/j.jchf.2012.10.0 02.

2. Fomin I.V. Chronic heart failure in the Russian Federation: what we know today and what we must do. Russian journal of cardiology. 2016; (8): 7-13. DOI: 10.15829/1560-4071-2016-8-7-13. [in Russian].

3. Alieva A.M., Reznik E.V., Hasanova E.T. Clinical significance of the determination of blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018; 8 (5): 333-345. DOI: 10.20514/2226-6704-2018-8-5-333-345. [in Russian].

4. Gasparyan A.Zh., Shlevkov N.B., Skvortsov A.A. Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure. Kardiologiia. 2020;60(4):101–108. DOI: 10.18087/cardio.2020.4.n487. [in Russian].

5. Emmerson P.J., Duffin K.L., Chintharlapalli S. et al. GDF15 and Growth Control. Front Physiol. 2018; 9:1–7. DOI: 10.3389/fphys.2018.01712

6. Kempf T., Eden M., Strelau J. et al. The transforming growth factorsuperfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98(3):351–60. DOI: 10.1161/01.RES.0000202805.73038.48

7. Ho J., Mahajan A., Chen M. et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem. 2012;58(11):1582-1591. DOI:10.1373/clinchem.2012.190322.

8. May B.M., Pimentel M., Zimerman L.I. et al. GDF-15 as a Biomarker in Cardiovascular Disease. Arquivos Brasileiros de Cardiologia. 2021;116(3):494-500. DOI: 10.36660/abc.20200426

9. Wang T., Liu J., McDonald C. et al. GDF 15 is a heart-derived hormone that regulates body growth. EMBO molecular medicine. 2017;9(8):1150-1164. DOI: 10.15252/emmm.201707604

10. Wollert K.C., Guba-Quint A., Torgerson J. et al. An automated assay for growth differentiation factor 15. The Journal of Applied Laboratory Medicine. 2017;1(5):510–21. DOI: 10.1530/EJE-12-0466

11. Kempf T., Horn-Wichmann R., Brabant G. et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clinical chemistry. 2007;53(2):284–91. DOI: 10.1373/clinchem.2006.076828

12. Wollert K.C., Kempf T., Wallentin L. et al. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clinical chemistry. 2017; 63:140–51. DOI: 10.1373/clinchem.2016.255174

13. Khan S.Q., Kelvin Ng., Dhillon O. et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. European heart journal. 2009;30(9):1057–65. DOI: 10.1093/eurheartj/ehn600

14. Anand I.S., Kempf T., Rector T.S. et al. Serial measurement of growthdifferentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122(14):1387–95. DOI: 10.1161/CIRCULATIONAHA.109.928846

15. Ho J.E., Lyass A., Courchesne P. et al. Protein biomarkers of cardiovascular disease and mortality in the community. Journal of the American Heart Association. 2018;7(14): e008108. DOI: 10.1161/JAHA.117.008108

16. Xie S., Lu L., Liu L . et al. Gro wth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: A meta-analysis of prospective studies. Clinical cardiology. 2019;42(5):513–23. DOI: 10.1002/clc.23159

17. Sinning C. Zengin E., Zeller T. et al. Candidate biomarkers in heart failure with reduced and preserved ejection fraction. Biomarkers. 2015;20(4):258–65. DOI: 10.3109/1354750X.2015.1068856

18. Sinning C., Kempf T., Schwarzl M. et al. Biomarkers for characterization of heart failure–distinction of heart failure with preserved and reduced ejection fraction. International journal of cardiology. 2017; 227: 272–7. DOI: 10.1016/j.ijcard.2016.11.110.

19. Chan M.M. Y., Santhanakrishnan R., Chong J.P. C. et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. European journal of heart failure. 2016;18(1):81–8. DOI: 10.1002/ejhf.431.

20. Santhanakrishnan R., Chong J.P. C., Tze P.Ng. et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. European journal of heart failure. 2012; 14(12):1338–47. DOI: 10.1093/eurjhf/hfs130.

21. Sharma A., Stevens S.R., Lucas J. et al. Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study. JACC: Heart Failure. 2017;5(10):724–34. DOI: 10.1016/j.jchf.2017.07.013.

22. Li J., Cui Y., Huang A. et al. Additional diagnostic value of growth differentiation factor-15 (GDF-15) to N-terminal B-type natriuretic peptide (NT-proBNP) in patients with different stages of heart failure. Medical science monitor: international medical journal of experimental and clinical research. 2018; 24:4992–9. DOI: 10.12659/MSM.910671.

23. Du H., Yang L., Zhang H., et al. Correlation between growth differentiation factor-15 and the severity of chronic heart failure in patients with coronary atherosclerosis. Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):12844-12848. DOI: 10.26355/eurrev_202012_24186.

24. Bouabdallaoui N., Claggett B., Zile M.R. et al. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. European journal of heart failure. 2018;20(12):1701–9. DOI: 10.1002/ejhf.1301.

25. Foley P.W. X., Stegemann B., Kelvin Ng. et al. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. European heart journal. 2009;30(22):2749–57. DOI: 10.1093/eurheartj/ehp300.

26. Lok D.J., Klip I.T., Lok S.I. et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. The American journal of cardiology. 2013;112(6):831–7. DOI: 10.1016/j.amjcard.2013.05.013.

27. Lok S.I., Winkens B., Goldschmeding R. et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. European journal of heart failure. 2012;14(11):1249–56. DOI: 10.1093/eurjhf/hfs120.

28. Drapkina O.M., Palatkina L.O. Markers of cytokine activation and oxidative stress in patients with chronic heart failure. Heart Failure 2013; 14 (6): 341-6. [in Russian].

29. Bazaeva E.V. Clinical picture, systolic and diastolic parameters of left ventricular myocardial function and biochemical marker levels in patients with chronic heart failure with different values of left ventricular ejection fraction: dissertation. Moscow, 2017. p. 25. [in Russian].

30. Kuzheleva E.A., Garganeeva A.A., Aleksandrenko V.A. et al. Associations of growth factor differentiation 15 with clinical features of chronic heart failure with intermediate and preserved ejection fraction depending on the history of myocardial infarction. Cardiology. 2021;61(5): 59-64. DOI: 10.18087/cardio.2021.5.n1449. [in Russian].

31. Sivolap V.D., Zemlyaniy Ya.V. Prognostic value of GDF 15 and NTproBNP levels and echocardiographic parameters in patients with heart failure with preserved ejection fraction and asymptomatic diastolic dysfunction who suffered myocardial infarction on the background of arterial hypertension. Zaporozhye Medical Journal. 2014;3(84):13–17. [in Russian].

32. Li J., Cui Y., Huang A. et al. Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure. Med Sci Monit. 2018; 24:4992-4999. DOI: 10.12659/MSM.910671.

33. Nair N., Gongora E. Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology? J Circ Biomark. 2018; 7:1849454417751735. DOI: 10.1177/1849454417751735.

34. Benes J., Kotrc M., Wohlfahrt P. et al. The Role of GDF-15 in Heart Failure Patients with Chronic Kidney Disease. Can J Cardiol. 2019;35(4):462-470. doi: 10.1016/j.cjca.2018.12.027.

35. Tuegel C., Katz R., Alam M. et al. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. Am J Kidney Dis. 2018 Oct;72(4):519-528. DOI: 10.1053/j.ajkd.2018.03.025.

36. Cotter G., Voors A.A., Prescott M.F. et al. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. European journal of heart failure. 2015;17(11):1133–43. DOI: 10.1002/ejhf.331.

37. Jankovic-Tomasevic R., Pavlovic S.U., Jevtovic-Stoimenov T. et al. Prognostic utility of biomarker growth differentiation factor-15 in patients with acute decompensated heart failure. Acta cardiologica. 2016;71(5):587–95. DOI: 10.2143/AC.71.5.3167503.

38. Boulogne M., Sadoune M., Launay J.M. et al. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. International journal of cardiology. 2017; 226:53–9. DOI: 10.1016/j.ijcard.2016.10.038.

39. Gizatulina T.P., Martyanova L.U., Petelina T.I. Growth differentiation factor 15 as an integral marker of the clinical and functional status of a patient with non-valvular atrial fibrillation. Bulletin of Arrhythmology. 2020;27(3):25-33. DOI: 10.35336/VA-2020-3-25-33.

40. Dalos D., Spinka G., Schneider M. et al. New Cardiovascular Biomarkers in Ischemic Heart Disease-GDF-15, A Probable Predictor for Ejection Fraction. J Clin Med. 2019;8(7):924. DOI: 10.3390/jcm8070924.

41. Manhenke C., Orn S., Haehling S. et al. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol. 2013;166(3):729-35. DOI: 10.1016/j.ijcard.2011.11.089.

42. Lourenço P., Cunha F.M., Ferreira-Coimbra J. et al. Dynamics of growth differentiation factor 15 in acute heart failure. ESC Heart Fail. 2021;8(4):2527-2534. DOI: 10.1002/ehf2.13377.

43. Nolte K., Gabriel F., Stahrenberg R. et al. GDF-15, MRproADM, CTproET1 und CTproAVP bei Patienten mit asymptomatischer diastolischer Dysfunktion [GDF-15, MRproADM, CTproET1, and CTproAVP in patients with asymptomatic diastolic dysfunction]. Dtsch Med Wochenschr. 2015;140(13): e120-8. German. DOI: 10.1055/s-0041-102543.

44. Zhang Y., Moszczynski L.A., Liu Q. et al. Over-expression of growth differentiation factor 15 (GDF15) preventing cold ischemia reperfusion (I/R) injury in heart transplantation through Foxo3a signaling. Oncotarget. 2017;8(22):36531-36544. DOI: 10.18632/oncotarget.16607.

45. Lodi R., Yu B., Xia L. et al. Roles and Regulation of Growth differentiation factor-15 in the Immune and tumor microenvironment. Hum Immunol. 2021: S0198-8859(21)00170-1. DOI: 10.1016/j.humimm.2021.06.007.

46. Bonaca M., Morrow D.A., Braunwald E.et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011;31(1):203-10. DOI: 10.1161/ATVBAHA.110.213512.

47. Zeng X., Li L., Wen H., Bi Q. Growth-differentiation factor 15 as a predictor of mortality in patients with heart failure: a metaanalysis. J Cardiovasc Med (Hagerstown). 2017;18(2):53-59. DOI: 10.2459/JCM.0000000000000412.

48. Hao J., Cheang I., Zhang L. et al. Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study. Chin Med J (Engl). 2019;132(19):2278-2285. DOI: 10.1097/CM9.0000000000000449.

49. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-62. DOI: 10.1161/CIRCULATIONAHA.104.482570.